Jane B Acri1, Alan J Cross2, Phil Skolnick3. 1. Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, 6001 Executive Blvd, Suite 4123, MSC 9551, Bethesda, MD, 20892-9551, USA. jacri@nih.gov. 2. AstraZeneca Neuroscience Innovative Medicines and Early Development Biotech Unit, 141 Portland Street, Cambridge, MA, 02139, USA. 3. Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, 6001 Executive Blvd, Suite 4123, MSC 9551, Bethesda, MD, 20892-9551, USA.
Abstract
OBJECTIVE: This paper provides an overview of the role of type 2 metabotropic glutamate receptors (mGluR2) in addiction and behaviors reflecting addictive processes. RESULTS: AZD8529, an mGluR2 positive allosteric modulator (PAM), failed to separate from placebo in a phase II schizophrenia trial. The demonstration by Athina Markou's laboratory that AZD8529 attenuated both nicotine self-administration and cue-induced reinstatement was a key factor in the decision to move this compound into a smoking cessation study. CONCLUSION: Here, we highlight Markou laboratory's contribution to this project, as well as several innovative features of the phase II clinical trial that has already completed enrollment with top line results expected in early 2017.
RCT Entities:
OBJECTIVE: This paper provides an overview of the role of type 2 metabotropic glutamate receptors (mGluR2) in addiction and behaviors reflecting addictive processes. RESULTS:AZD8529, an mGluR2 positive allosteric modulator (PAM), failed to separate from placebo in a phase II schizophrenia trial. The demonstration by Athina Markou's laboratory that AZD8529 attenuated both nicotine self-administration and cue-induced reinstatement was a key factor in the decision to move this compound into a smoking cessation study. CONCLUSION: Here, we highlight Markou laboratory's contribution to this project, as well as several innovative features of the phase II clinical trial that has already completed enrollment with top line results expected in early 2017.
Authors: Khaled Moussawi; Wenhua Zhou; Haowei Shen; Carmela M Reichel; Ronald E See; David B Carr; Peter W Kalivas Journal: Proc Natl Acad Sci U S A Date: 2010-12-20 Impact factor: 11.205
Authors: Zhifeng Zhou; Camilla Karlsson; Tiebing Liang; Wei Xiong; Mitsuru Kimura; Jenica D Tapocik; Qiaoping Yuan; Estelle Barbier; Austin Feng; Meghan Flanigan; Eric Augier; Mary-Anne Enoch; Colin A Hodgkinson; Pei-Hong Shen; David M Lovinger; Howard J Edenberg; Markus Heilig; David Goldman Journal: Proc Natl Acad Sci U S A Date: 2013-09-30 Impact factor: 11.205
Authors: Thomas M Shiovitz; Earle E Bain; David J McCann; Phil Skolnick; Thomas Laughren; Adam Hanina; Daniel Burch Journal: J Clin Pharmacol Date: 2016-01-22 Impact factor: 3.126
Authors: Daniel H Wolf; David Zheng; Christian Kohler; Bruce I Turetsky; Kosha Ruparel; Theodore D Satterthwaite; Mark A Elliott; Mary E March; Alan J Cross; Mark A Smith; Stephen R Zukin; Ruben C Gur; Raquel E Gur Journal: Mol Psychiatry Date: 2021-10-20 Impact factor: 13.437